Enzalutamide Tablets 160mg
ENZALIEVA Enzalutamide Tablets 160mg is an advanced anticancer medicine used for the treatment of prostate cancer in adult patients. It contains Enzalutamide, a powerful androgen receptor inhibitor that helps slow down the growth and spread of prostate cancer cells. This medicine is commonly prescribed by oncologists as part of hormone therapy for patients suffering from advanced or metastatic prostate cancer.
Prostate cancer is one of the most common cancers affecting men worldwide. Cancer cells in the prostate often depend on male hormones called androgens, especially testosterone, for growth and survival. Enzalutamide works by blocking the action of these hormones, helping reduce the ability of cancer cells to grow and multiply. Due to its targeted mechanism of action, ENZALIEVA is widely used in modern oncology treatment protocols for prostate cancer management.
ENZALIEVA Enzalutamide Tablets 160mg is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. The medicine is commonly recommended in patients with:
Metastatic castration-resistant prostate cancer (mCRPC)
Non-metastatic castration-resistant prostate cancer (nmCRPC)
Metastatic hormone-sensitive prostate cancer (mHSPC)
This anticancer medicine is usually prescribed when prostate cancer continues to progress despite reduced testosterone levels or hormonal treatment. Doctors may use ENZALIEVA alone or in combination with other therapies depending on the patient’s condition, cancer stage, and overall treatment plan.
Enzalutamide Tablets are known for helping improve disease management by delaying cancer progression and supporting overall treatment outcomes. The medicine has become an important part of prostate cancer therapy due to its effectiveness in controlling androgen receptor activity, which plays a major role in prostate cancer growth.
Patients should use this medicine strictly under the supervision of qualified healthcare professionals. Proper medical monitoring and regular health checkups are important during treatment to ensure better response and patient safety.
View Details
Bicalutamide Tablet IP 50mg
BICALIEVA 50MG (Bicalutamide Tablet IP 50mg) is a prescription anti-cancer medicine used in the treatment and management of prostate cancer. It contains Bicalutamide 50mg, a non-steroidal antiandrogen that works by blocking the effects of male hormones (androgens), particularly testosterone, which can stimulate the growth of prostate cancer cells.
Prostate cancer is one of the most commonly diagnosed cancers in men worldwide. Many prostate cancer cells rely on testosterone and other androgens to grow and multiply. BICALIEVA 50MG helps control the disease by preventing these hormones from attaching to cancer cells, thereby slowing cancer growth and reducing tumor progression.
Bicalutamide is widely used as part of hormone therapy for prostate cancer and is often prescribed in combination with other treatments such as luteinizing hormone-releasing hormone (LHRH) agonists or surgical castration. This combined approach helps achieve more effective androgen deprivation, which is an important strategy in prostate cancer management.
BICALIEVA 50MG is commonly prescribed for:
• Advanced Prostate Cancer
• Metastatic Prostate Cancer
• Hormone-Sensitive Prostate Cancer
• Androgen Deprivation Therapy (ADT)
• Combination Prostate Cancer Treatment
• Long-Term Oncology and Urology Care
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in oncology and urology treatment.
Patients receiving BICALIEVA 50MG may require regular monitoring of prostate-specific antigen (PSA) levels, liver function, overall treatment response, and routine medical evaluations. These assessments help healthcare providers optimize treatment outcomes and manage potential side effects effectively.
Due to its proven role in hormone-based prostate cancer treatment, BICALIEVA 50MG remains an important medicine in modern oncology and urology care programs.
View Details
Abiraterone Acetate Tablets IP 500mg
ABIRALIEVA 500 mg contains Abiraterone Acetate, an oral androgen biosynthesis inhibitor. It blocks the enzyme CYP17 (17α-hydroxylase/17,20-lyase), which is essential for androgen production in the testes, adrenal glands, and prostate tumor tissue. This results in profound suppression of circulating and intratumoral androgens, slowing prostate cancer growth.
View Details
Abiraterone Acetate Tablets IP 25mg
ABIRALIEVA 250 mg contains Abiraterone Acetate, an oral androgen biosynthesis inhibitor. It works by irreversibly inhibiting CYP17 (17α-hydroxylase/17,20-lyase), an enzyme essential for androgen production in the testes, adrenal glands, and prostate tumor tissue. This leads to profound suppression of androgen levels and slows prostate cancer progression.
View Details
Enzalutamide Capsules 40mg
ENZALIEVA 40 mg contains Enzalutamide, an oral androgen receptor (AR) inhibitor. It works by blocking androgen receptor signaling at multiple steps—preventing androgen binding, nuclear translocation, and DNA interaction—thereby inhibiting prostate cancer cell growth.
View Details
Enzalutamide Capsules 40mg
ENZALIEVA 40 mg contains Enzalutamide, an oral androgen receptor (AR) inhibitor. It works by blocking androgen receptor signaling at multiple steps—preventing androgen binding, nuclear translocation, and DNA interaction—thereby inhibiting prostate cancer cell growth.
View Details
